Paxlovid & Tollovid Overtake Ivermectin & Open Door for Long-COVID Sufferers

A lot of studies have been done on Ivermectin, but the latest study might finally have the right stuff to settle the debate.  The New England Journal of Medicine (NEJM) scientifically roasted Ivermectin and demonstrated that Ivermectin didn’t lower the incidence of hospitalization which was the primary outcome of the study. Many advocates of Ivermectin like podcaster Joe Rogan dismissed the research in the past, but this time there was no reaction.  This silence has created an ominous vacuum for the legions of Ivermectin fans that think they have nothing to turn to.  Vacuums get filled and Tollovid might be the answer for not only Ivermectin fans but Long Haulers. 

Many Ivermectin zealots that understand the science, realize that 3CL protease inhibition is the key mechanism of action (MOA).  Pfizer’s drug Paxlovid earned a EUA for its 3CL protease inhibitor, but it has restrictions and is only available for people with underlying medical conditions. Close to 60% of the population of the United States has chronic underlying medical conditions which increase their risk of severe COVID-19.  That leaves 40% of the population without any treatment options.

Paxlovid Unlikely for Mass Distribution

Those healthy individuals thinking about the FDA expanding the use of Pfizer’s Paxlovid need to go back to the drawing board with a new plan.  Paxlovid is a combination of two drugs, Ritonavir, an HIV medicine, and Nirmatrelvir, a 3CL protease inhibitor.  This is not a drug for kids or a healthy person.  Ritonavir has a blackbox label which could lead to life-threatening reactions.  Nirmatrelvir is a very potent 3CL protease inhibitor that stops viral replication but it’s very active and at higher doses could lead to toxicity.  Ritonavir slows down the liver’s metabolism of the drug allowing it to work without reaching the point of toxicity.  In fact, Paxlovid has a lot of drug-to-drug interactions that end up disqualifying many from being prescribed its use like people with liver or kidney disease and it’s a no for pregnant women. This is why even Molnupiravir, a mutagenic drug, outpaced Paxlovid use in February 2022 by 4 to 1. There is no real large supply of Paxlovid expected until the Fall so very little chance that this can fill the Ivermectin vacuum.

Related:  The Inevitable Recession

All Natural Nutraceutical Takes Center Stage

Ivermectin is a very weak 3CL protease inhibitor.  It works by binding to the 3CL protease used to create more virion, but it takes a very high dose to neutralize all the proteases.  As COVID-19 mutated the variants became more virulent and had notably higher viral loads.  Based on science, unsafe levels of Ivermectin would be needed to block enough protease to stop the infection from the Omicron variant.  Tollovid is a plant-based all-natural nutraceutical with a 3CL protease inhibitor that is 10 – 25 times more powerful in terms of binding affinity than Ivermectin.  The FDA-approved 3CL protease inhibitor is an all-natural product that has an excellent safety profile and can be taken for long periods of time without any effect. Although the supplement is not intended to prevent, cure, or treat any disease, it is easy to connect the dots and understand the benefits of inhibiting 3CL. 

The nutraceutical is priced lower than Paxlovid and on the high end of dietary supplements.  The supplement apparently works when it comes to viral challenges against 3CL.  The reviews really tell the tale.  It’s available for consumption NOW and can be purchased through or  There is one formulation with 2 use cases.  One regimen is for daily use and the other is for an active infection.  Unlike Ivermectin the consumer isn’t limited by the dosage.  If the consumer needs more 3CL protease inhibition because they aren’t getting better fast enough they can simply take more without any blowback.  

Understanding Ivermectin’s IC50

The NEJM study tested what would be considered a high dose of the drug to prevent COVID-19 hospitalizations. The results were not statistically significant but showed a trend of reducing hospitalization rates from 16.5% to 14.7%. For the average person, it’s worth trying to find a solution that works better than reducing the risk of hospitalization by about 1.8%. The IC50 of Ivermectin is 50 which is far below what is considered the therapeutic level of 2-5.  IC50 measures the potency of a substance inhibiting a specific biological target, in this case, it is 3CL protease.  The CEO of Todos Medical talked about this in an interview that gets into the IC50 of the various 3CL protease inhibitors. The CEO did say “People who say I might have had some benefit are not crazy.” Everyone’s immune system is different and early in the pandemic, the viral loads were not as high. That seems to explain his rationale. The video short is a must-see for every Ivermectin fan.     

Related:  The Great Reset: Turning Back The Clock On Civilization

Long Hauler study    

Long Haulers are a group of up to 30% of people that have contracted COVID-19. The prevalent theory is that Long-COVID is caused by viral persistence.  The idea is that coronavirus remains in the body in some form for people after they are infected with COVID-19.  Elimination of these hidden viral reservoirs would in turn eliminate the symptoms of Long-COVID.  Both Pfizer and Todos Medical announced case studies using Paxlovid and Tollovid.  Paxlovid improved Long-COVID symptoms 3 days into the 5-day regimen.  This patient had Long-COVID for 7 months and got back to her pre-COVID lifestyle right away.  This is a phenomenal case study but Long Haulers cannot get Paxlovid without a prescription and a COVID-19 positive test.  The Tollovid Case Study chronicled a Long-COVID patient who was so disabled she couldn’t work for 12 weeks.  After a 5 day course of over-the-counter Tollovid, she was able to return to work within a week.   This case study is actionable for 1.6 million-plus Long-COVID patients who might think they have viral persistence and want to try a 3CL protease inhibitor.  If the study of sniffer dogs that can detect active COVID-19 is correct then there is about a 51.1% chance that Long-COVID might be treatable with this all-natural supplement called Tollovid.    

Related:  Head of Bayer Admits COVID-19 Vaccine is Gene Therapy

The Next Ivermectin – Tollovid

Coming down with COVID-19 is an unpleasant experience which is why Ivermectin took off as a preventative treatment option.  Early in the pandemic, there were no real scientific studies, just anecdotes that had a reasonable scientific basis that ultimately linked to 3CL protease inhibition to fighting COVID-19. While the NEJM study might have crushed the scientific basis for Ivermectin, it didn’t crush the demand for an Ivermectin-like solution.  Many people want something that they can take when they want and do not have a doctor or CDC tell them what they can or can’t do.  If it’s safe and there is no downside to taking something, why not try is the thinking of this group of people. 

Tollovid fits this description really well but there is a caveat.  Tollovid the nutraceutical is 98% derived from a drug called Tollovir which is a more concentrated form of the botanical that was used in a phase 2 clinical trial in Israel.  In this randomized double-blind clinical trial of hospitalized patients, there were zero deaths in severe to critical patients versus 22% death rate in the control group.  The control group got the standard of care which included remdesivir and dexamethasone.  The point of this line of reasoning is that while the Tollovid bottle can’t say it works on COVID-19 or Long-COVID it does say it’s a 3CL protease inhibitor.  How big are the dots to connect between Paxlovid a 3CL protease inhibitor and COVID or Tollovir a 3CL inhibitor that took dying off the table in Hospitalized COVID-19 patients? Get ready for the next wave or get rid of that Long-COVID.

Original Article

Leave a Comment